Diabetes Metab J.  2024 Sep;48(5):882-884. 10.4093/dmj.2024.0479.

Ideal Combination of Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus

• Kim HS

• KMID: 2558998
• DOI: http://doi.org/10.4093/dmj.2024.0479

Reference

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58:773–95.

2. Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023; 47:575–94.

3. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022; 65:1925–66.

4. American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024; 47(Suppl 1):S158–78.

5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macr'oVascular Events): a randomised controlled trial. Lancet. 2005; 366:1279–89.

6. Heo JH, Han KA, Hong JH, Seo HA, Hong EG, Yu JM, et al. Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial. Diabetes Metab J. 2024; 48:937–48.

7. Cho YK, Kim KS, Lee BW, Hong JH, Yu JM, Lim S, et al. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study. Clin Ther. 2024; Jul. 26. [Epub]. https://doi.org/10.1016/j.clinthera.2024.06.023.

8. Anson M, Henney AE, Zhao SS, Ibarburu GH, Lip GYH, Cuthbertson DJ, et al. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: a systematic review, meta-analysis, and real-world study from an international federated database. Diabetes Obes Metab. 2024; 26:2606–23.

9. Lo SC, Kornelius E, Liao PL, Huang JY, Yang YS, Huang CN. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract. 2023; 200:110685.